Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

Abstract

Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy available to them. This reality has prompted development of many novel immunotherapeutics. Many of these drugs exploit the cytotoxic capabilities of the patients’ own T cells, effectively redirecting them to myeloma cells that are otherwise evading immune attack. Approaches including CAR T cell therapy and bispecific antibodies have displayed impressive efficacy in clinical trials for myeloma patients. This review examines the different approaches that utilize T cells in multiple myeloma therapy and investigates the benefits and risks of these exciting new strategies.

Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma

“… 10 However, the survival benefits of ASCT are limited. 11 The addition of IMiDs, PIs, and other new drugs and the improvement of maintenance therapy further improved the progression-free survival (PFS) and overall survival (OS) of MM patients. However, the problems of relapse and drug resistance still exist, and drugs with new mechanisms of action need to be developed for relapsed/refractory multiple myeloma (RRMM).…”